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RIASSUNTO  
Introduzione.  L’iperaldosteronismo primario (PA) è la forma più comune di 
ipertensione arteriosa secondaria da causa endocrina.  Per distinguere le forme 
chirurgicamente guaribili da quelle che esigono la sola terapia medica, le attuali 
linee guida dell’Endocrine Society raccomandano l'esecuzione del cateterismo 
venoso surrenalico (AVS), un’indagine ritenuta invasiva, rischiosa, tecnicamente 
difficile e di ardua interpretazione.  Tuttavia non è ancora del tutto noto, se e come 
queste linee guida vengano applicate ed interpretate nella pratica clinica.  Questo 
studio, the Adrenal Vein sampling International Study (AVIS), è stato ideato con 
l’intento di chiarire le modalità di utilizzo ed interpretazione dell’ AVS nei centri 
mondiali di riferimento. 
Materiali e metodi.  E’ uno studio retrospettivo, osservazionale, multicentrico, 
internazionale ed i centri partecipanti sono stati scelti tra quelli che hanno 
pubblicato dati su PA e AVS nella letteratura scientifica inglese nel periodo 
compreso tra il 2005 e il 2010.  Lo studio prevede 2 fasi: la prima ha lo scopo di 
raccogliere i dati relativi alle modalità di esecuzione ed interpretazione dell’AVS, 
mentre la seconda di raccogliere i dati individuali dei pazienti sottoposti al AVS. 
Obiettivi dello studio.  I principali obiettivi della prima fase dello studio sono stati 
quelli di chiarire una serie di quesiti irrisolti inerenti all’utilizzo e alla performance 
diagnostica dell’AVS per la diagnosi di PA.  In particolare, ci si è proposti di 
accertare: 1) la percentuale di pazienti con PA che vengono sottoposti ad AVS ed il 
numero di AVS eseguiti presso i maggiori centri internazionali di riferimento; 2) il 
tasso di complicanze (intese come rotture delle vene surrenaliche verificatesi 
durante l’AVS) e gli eventuali predittori delle stesse; 3) le modalità d’esecuzione 
dell’AVS; 4) le modalità di interpretazione ed utilizzo dei suoi dati; 5) la 
percentuale di utilizzo degli indici di selettività, di lateralizzazione e soppressione 
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controlaterale ed i loro valori di riferimento; 6) il costo di AVS per il paziente ed il 
sistema sanitario dei diversi paesi.   
Nella seconda parte dello studio sono stati raccolti i dati individuali dei pazienti  
sottoposti all’AVS per: valutare il tasso di AVS bilateralmente selettivi in funzione 
dei diversi valori soglia dell'indice di selettività; identificare il miglior valore soglia 
che identifica la lateralizzazione dell’aldosterone; chiarire se la soppressione 
controlaterale permette la diagnosi di lateralizzazione in presenza di AVS solo 
unilateralmente selettivi;  valutare il tasso dei pazienti con ipersecrezione 
unilaterale dell’ aldosterone curata con la surrenectomia; stabilire se la terapia 
medica induce ad un miglioramento della pressione arteriosa in soggetti con 
ipersecrezione bilaterale del aldosterone; valutare la concordanza / discordanza tra 
test radiologici ed AVS nella diagnosi di lateralizzazione di aldosterone.  Per motivi 
di tempo e di brevità di questa analisi preliminare, i dati sulla soppressione 
controlaterale non saranno inclusi. 
Risultati.  Fase 1: sono stati raccolti dati su 2604 AVS eseguiti presso 20 centri 
mondiali di riferimento sparsi in Europa, Asia, Nord America e Australia.  
Dall’analisi dei risultati è emerso che la percentuale di pazienti con PA, 
sistematicamente sottoposti all’AVS, è pari al 77%, con un’ampia variabilità tra i 
diversi centri (dal 40% al 100%).  La percentuale di complicanze è risultata pari allo 
0.61%, con correlazione significativa tra il numero di complicanze ed il numero di 
AVS eseguiti presso ogni singolo centro (p=0.002) e correlazione inversamente 
proporzionale al numero di AVS eseguiti dal singolo radiologo (p=0.007). 
Il numero di radiologi che eseguono l’AVS nei singoli centri è mediamente di 2 
radiologi/centro (variabile tra 1 e 7) ad eccezione di 2 centri, dove rispettivamente 
6 e 7 radiologi erano coinvolti nell’esecuzione della procedura.  La maggior parte 
dei centri (13/20) utilizza il cateterismo sequenziale e solo 7 centri il cateterismo 
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simultaneo bilaterale.  Per quanto riguarda l’impiego del test di stimolazione con 
ACTH i centri si sono distribuiti quasi equamente tra quelli che utilizzano tale 
stimolazione (55%) e quelli che non la utilizzano (45%).  Dalle analisi non è emersa 
una correlazione tra il cateterismo sequenziale e l’utilizzo del test di stimolazione 
con ACTH.  
L’indice di selettività (SI) viene calcolato nel 90% dei centri ed i suoi valori di 
riferimento variano da 1.1 a 3 in condizioni basali e da 2 a 10 dopo la stimolazione 
con ACTH.  Un centro utilizza solo i valori ormonali assoluti, mentre un altro 
centro non calcola il SI ma solo gli indici di lateralizzazione e soppressione 
controlaterale.  L’indice di lateralizzazione (LI) è calcolato nel 95% dei centri ed i 
suoi valori di riferimento variano da 2 a 5 in condizioni basali e da 2 a 4 dopo la 
stimolazione con ACTH. L’indice di soppressione controlaterale (CSI) viene 
calcolato in 65% dei centri e i suoi valori di riferimento variano da 0.5 a 1 in 
condizioni basali e da 0.9 a 1 dopo la stimolazione con ACTH.  Non è emersa una 
correlazione significativa tra l’utilizzo della stimolazione con ACTH ed il calcolo 
del CSI.  In caso di non disponibilità di AVS bilateralmente selettivi, il 60 % dei 
centri utilizza per diagnosi anche gli AVS non selettivi bilateralmente.  E’ stata 
trovata una correlazione significativa (p=0.05) tra l’uso di AVS non selettivi ed il 
calcolo del CSI.  Per quanto riguarda i costi dell’AVS, i risultati di questa analisi 
hanno evidenziato un’ampia variabilità tra i diversi centri ed i diversi paesi.  Il 
costo del singolo AVS varia da 80 a 10.532 euro per il sistema sanitario nazionale e 
da 0 a 1.357 euro a carico del paziente.  
Fase 2: l’analisi dei dati della seconda fase dello studio è stata eseguita solo su dati 
parziali, a causa del ritardato inserimento degli stessi da parte di alcuni centri.  In 
questa analisi preliminare sono state raccolte informazioni su 1.030 pazienti con 
PA sottoposti all’ AVS, provenienti da 15 centri differenti.  Il 43% dei pazienti 
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presentava ipertensione arteriosa resistente, il 59% era di sesso maschile e la razza 
caucasica era quella predominante.    
L’analisi del miglioramento della pressione arteriosa, indipendentemente dal tipo 
di trattamento (medico o chirugico), al follow up ha evidenziato il 19% di pazienti 
normotesi, il 49% con significativo miglioramento della pressione - definita come 
pressione arteriosa normale con lo stesso o ridotto numero di farmaci e/o pressione 
arteriosa simile a quella basale, ma con una marcata diminuzione di farmaci (> 2 
farmaci) - , il 25% ha presentato solo un lieve miglioramento della pressione 
arteriosa - riduzione della pressione arteriosa sistolica o distolica >10%, senza il 
raggiungimento della normotensione con lo stesso o ridotto numero di farmaci - ,  
mentre,  l’  8% dei casi non ha presentato alcun miglioramento.  Le donne ed i 
soggetti di razza caucasica o africana presentavano un outcome migliore.  Per 
quanto riguarda l’outcome pressorio nei pazienti surrectomizzati, al follow up,  il 
34% dei pazienti era normoteso, il 45% con significativo miglioramento della 
pressione, il 16% ha presentato solo un lieve miglioramento e nel  5% dei casi non 
c’era alcun miglioramento.  Dall’analisi è stata evidenziata anche la bassa 
percentuale di pazienti sottoposti alla surrenectomia, in media il 53% dei pazienti, 
con ampia variabilità tra i diversi centri. Per quanto riguarda il controllo della 
pressione arteriosa con la sola terapia medica nei soggetti con ipersecrezione 
bilaterale di aldosterone, la maggioranza (circa il 75%) ha presentato solo un lieve 
miglioramento del controllo pressorio, mentre nel 24% dei casi non c’era alcun 
miglioramento.  
La valutazione del tasso di AVS bilateralmente selettivi in funzione dei diversi 
valori-soglia dell'indice di selettività, ha evidenziato che, l’aumento del numero di 
AVS bilateralmente selettivi, era inversamente proporzionale al valore soglia del 
SI, sia in condizioni basali che dopo lo stimolo con ACTH.  Per identificare il 
miglior valore soglia che identifica la lateralizzazione dell’aldosterone, sono stati 
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esaminati i pazienti con AVS bilateralmente selettivi, con evidenza di 
ipersecrezione unilaterale di aldosterone, sottoposti a surrenectomia, che al follow 
up presentavano l’ipertensione arteriosa curata o significatamene migliorata.  
Questa analisi ha evidenziato che, ad ogni SI, maggiore è il valore soglia che 
identifica la lateralizzazione dell’aldosterone, più alto è il tasso di pazienti con 
ipertensione arteriosa curata o significatamene migliorata. 
Per quanto riguarda la concordanza tra test radiologici ed AVS nella diagnosi di 
lateralizzazione di aldosterone, l’analisi condotta nel gruppo di pazienti con AVS 
bilateralmente selettivo, con evidente lateralizzazione dell’aldosterone, sottoposti 
alla surrenectomia, ha evidenziato concordanza tra i 2 test diagnostici in solo il 
57% dei casi a destra e il 65% dei casi a sinistra.   
Conclusioni.  Nonostante il fatto che il PA sia la forma più comune di ipertensione 
arteriosa secondaria da causa endocrina e che l’AVS sia ritenuto indagine “gold 
standard” per la diagnosi differenziale tra i suoi due principali sottotipi, e quindi 
per la scelta del trattamento più appropriato (medico o chirurgico), i risultati della 
prima fase dello studio AVIS hanno documentato l’esistenza di marcate diversità 
nella percentuale di utilizzo, nelle modalità d’esecuzione e d’interpretazione nei 
diversi centri di riferimento mondiali. 
Lo studio ha evidenziato un tasso di complicanze globalmente minimo, pari allo 
0.61%.  Quindi nonostante l’AVS sia generalmente considerato un’indagine 
invasiva, in realtà in presenza di mani esperte, esso risulta essere sicuro. Questo 
dato conferma le raccomandazioni delle attuali linee guida dell’Endocrine Society 
di sottoporre ad AVS tutti i pazienti con PA in assenza di controindicazioni al 
trattamento chirurgico. 
La fase 2 dello studio attraverso l’analisi dei dati individuali ha evidenziato che la 
scelta di valori più restrittitivi dell’indice di selettività e dell’indice di 
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lateralizzazione si traduce in maggiori tassi di guarigione e miglioramento 
dell’ipertensione arteriosa, al prezzo dell’esclusione di un numero maggiore di 
pazienti dalla surrenectomia. 
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ABSTRACT 
Context.  Primary aldosteronism (PA) is the most common form of secondary 
endocrine hypertension.  To make a distinction between surgically-curable and 
surgically-non curable causes, the Endocrine Society guidelines recommend the 
use of adrenal venous sampling (AVS), which is considered invasive, technically 
challenging, difficult to interpret, and commonly held to be risky.  However, 
whether and how these guidelines are interpreted in clinical practice is still 
unknown.  Hence, the purpose of this PhD work was to set up a study, the Adrenal 
Vein sampling International Study (AVIS), to answer several questions concerning 
AVS. 
Design and settings.  AVIS is an observational, retrospective, multicenter 
international study.  The eligible centers were identified among those that had 
published data about PA and/or AVS into English scientific literature during the 
period between 2005 and 2010.   The study is designed in two phases, the first one 
is aimed to collect the data on AVS while the second one, the data on single 
patients. 
Objective.  In the first phase of the study, the main outcomes were to determine 
the complication rate of AVS and the ways in which it is performed and interpreted 
at major referral centers.  Specifically, the rate of PA patients in whom AVS is 
performed and the  number of AVS studies performed yearly between 2005 and 
2010 per each center; the number of radiologists that perform AVS at each center 
and the rate of complication; the use of bilaterally simultaneous or sequential AVS 
catheterization and the use of cosyntropin stimulation during AVS; the use of AVS 
studies not bilaterally selective for diagnosis; the interpretation of AVS results by 
calculation of the selectivity, lateralization and contralateral suppression index and 
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minimum cutoff value used; the cost of AVS for the National Health 
System/Insurance and for patients.  
The second phase is aimed to collect individual patients data to assess the rate of 
bilaterally selective AVS studies as a function of the different cutoff values of the 
selectivity index; to identify the best cutoff value for the identification of the 
lateralized aldosterone excess; to clarify if contralateral suppression allows 
diagnosing lateralization when only unilateral (usually left-sided) AVS is 
successful; to assess the rate of the patients with lateralized aldosterone excess 
secretion cured by adrenalectomy; to establish whether medical therapy induces 
improvement of high blood pressure (BP) in PA subtypes characterized by bilateral 
aldosterone excess secretion; assess the rate of AVS concordant /discordant with 
results of imaging tests. For reasons of time and brevity in this preliminary analysis 
the data on contralateral suppression will not be included. 
Results.  Phase 1: Twenty out of 24 eligible centers from Europe, Asia, Australia 
and North America participated and provided information on 2604 AVS studies 
performed between 2005 and 2010.  The percentage of PA patients systematically 
submitted to AVS was 77% (median, range: 19%-100%).  The overall rate of adrenal 
vein rupture was 0.61% and it correlated directly with the number of AVS 
performed at a particular center (p=0.002) and inversely with the number of AVS 
performed by each radiologist (p=0.007).  The total number of radiologists who 
performed AVS at the 20 centers was 51 (range, 1 to 7; median,2).  Thirteen of the 
20 centers used sequential and 7 bilaterally simultaneous catheterization; 
cosyntropin stimulation was used in 11 centers.  No significant correlation has been 
found between the use of ACTH stimulation and sequential catheterization. 
The cutoff values for selectivity and lateralization indices varied markedly among 
those centers that systematically used them.  Selectivity index (SI) results to be 
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calculated in 90% of the centers, and the cut off values varied under non-stimulated 
condition from 1.1 to 3, and under stimulate conditions between 2 and 10.  
Lateralization index (LI) is used in 95% of the centers and its cut off values varied 
under non-stimulated condition from 2 to 5, and under stimulate conditions 
between 2 and 4.  Contralateral suppression index (CSI) was calculated in 65% of 
the centers and its cut off values varied under non-stimulated condition from 0.5 
to 1, and under stimulate conditions between 0.9 and 1. 
It was  found out that 60% of centers used unilaterally selective studies when 
bilateral results were unavailable for the diagnosis and there was significant 
correlation between use of unilateral selective AVS and contralateral suppression 
(p=0,05).  In contrast, no significant correlation was found between the use of 
ACTH stimulation and contralateral suppression.  The costs of AVS showed a wide 
variability among centers and countries, both for the patient and for the insurance 
or national health care system.  The cost ranged from 80 (€) to 10,532 € for health 
insurance systems and from 0 to 1,357 € for the patient. 
Phase 2: Due to the delay of some centers in providing the data, we performed a 
preliminary analysis only with the available data.  We collected information on 
1.030 PA patients who underwent AVS in 13 referral centers worldwide.   Resistant 
hypertension was found in 43% of the patients, 59% were men; the majority were 
Caucasians. 
The analysis of overall improvement at follow up of high BP with either 
pharmacological or surgical treatment evidenced 19% of patients with cured high 
BP, 49% of patients with a markedly improved BP control, 25% with only a mild 
improvement of BP and 8% with no improvement of BP.  The analysis evidenced 
that women, Caucasian and African had better outcomes.   
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As regards the outcome of BP in the adrenalectomized patients, BP was cured in 
34% of cases, markedly improved in 45% of patients, mildly improved in 16% of 
patients and no improvement in 5% of the patients.  Moreover, the rate of patients 
who underwent adrenalectomy was lower than expected (median 53%) with a high 
variability among centers.  The analysis evidenced that in the patients with 
bilateral aldosterone excess no cases showed cured o markedly improved control 
of high BP while on pharmacological treatment.  At follow up, the majority of the 
patients (about 75%) showed only a mildly improved control of BP, and 24% of the 
patients had no improvement. 
The analysis of the rate of bilaterally selective AVS studies as a function of different 
cutoff values showed that lower SI cutoff values were associated with a higher rate 
of bilaterally selective studies.  To evaluate the best cutoff value for identifying a 
lateralized aldosterone excess we examined the bilaterally selective studies (by 
different SI cutoffs), the performance of the different LI used across the centers 
using as reference index cure or marked improvement of BP at follow up after the 
adrenalectomy.  This evidenced that, at each SI, the higher the LI cutoff the higher 
the rate of patients who were cured or markedly improved as far as BP control. 
As regards the rate of concordance/discordance between AVS results and CT 
imaging results for the diagnosis of lateralized aldosterone excess, we performed 
the analysis in patients with bilaterally selective AVS, with evidence of lateralized 
aldosterone excess, who undergo to adrenalectomy and at follow up presented 
cured o markedly improved BP.  This analysis evidence that in this subgroup of 
patients the rate of concordance between AVS results and CT imaging results was 
low, 65% on the left side and 57% on the right side.  
 Conclusions.  Despite the high prevalence of PA, and the fact that AVS is crucial 
for discriminating between its two major subtypes, and therefore for selecting the 
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most appropriate treatment, this study documented marked dissimilarities in the 
percentage of use, protocols, interpretation and cost of AVS even among the major 
referral centers around the world.  Importantly, overall the rate of major 
complications was minimal, 0.61%, which demonstrates that although being 
generally regarded as a risky procedure, AVS is in truth safe in experienced hands.  
This observation therefore supports the Endocrine Society recommendation that 
AVS should be used in all patients with confirmed PA who are candidate for 
adrenalectomy and seek surgical cure.  
In the second phase of the study, analysis of the individual patients data, evidence 
that a choice of more restrictive values of the selectivity and the lateralization 
index, translates to increased rates of cured and markedly improved BP at follow 
up, but this at the price of the exclusion of a greater number of patients from 
adrenalectomy. 
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1. INTRODUCTION 
 
1.1  Definition and consequences of primary aldosteronism 
Primary aldosteronism (PA) is a syndrome characterized by overproduction of 
aldosterone, independent of angiotensin II.  Patients present with hypertension, a 
suppressed plasma rennin activity (PRA), varying degrees of metabolic alkalosis, 
while hypokalemia and hypomagnesemia are not consistent findings.  Patients 
may have a variable presentation, many subjects will have symptoms that include 
muscle aches, cramping and weakness, headaches, palpitations, and polyuria.(1)  
However, other subjects have minimal or no symptoms at all, and in some rare 
cases, the subject can present with normal blood BP.(2-4) 
PA is the most common form of secondary endocrine hypertension.  It was first 
described in 1953 in Polish literature by Litynski,(5) who reported about two 
patients with progressive hypertension and adrenal masses and suggested that 
mineralocorticoids were responsible for the hypertension.  This report went 
unrecognized in the English language scientific literature until 1991.(6)  Hence, the 
credit for the first report of PA is usually given to Jerome Conn who in 1959(7) 
reported the case of 34-year-old woman who had a syndrome of ‘moderate 
hypertension’, hypokalemia, metabolic alkalosis, mild hypernatremia and normal 
renal function.   
Evidence exists that PA is associated with an excess target organ damage.  This is 
because hyperaldosteronism produces oxidative stress(8, 9) oxidative damage to 
DNA,(10) inflammation,(11) cardiovascular remodeling, hypertrophy, and 
fibrosis.(12, 13)  All of these effects explain why primary aldosteronism was found 
to impair left ventricular filling and diastolic function,(14) induce fibrosis of the 
left ventricular wall,(15) prolong the ECG PQ interval,(16) induce the endothelial 
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dysfunction,(17-19) stiffening of the large arteries,(20-21)  remodeling of resistance 
arteries,(21) stroke,(22) and micro-albuminuria.(23-26)  These changes translate 
into an elevated rate of cardiovascular events of PA patients, including atrial 
fibrillation, ischemic stroke, cerebral hemorrhage,(27, 28) “flash”pulmonary 
edema, and myocardial infarction.(29)  
Milliez et al.(29) reported a higher found of cardiac events in subjects with PA 
compared to essential hypertension (EH).  In fact, by evaluating retrospectively 
patients with PA compared to patients with hypertension, they found that the odds 
ratio of incidence of stroke, non-fatal myocardial infarction and atrial fibrillation 
was times higher in those with PA compared to those with EH.   
In a recent study, Savard et al.(30) compared the cardiovascular event rates in 
patients with PA to control patients with EH, who were matched for age, gender 
and systolic BP.  Patients with PA had a 2-fold higher likelihood of having left 
ventricular hypertrophy than subjects with EH in this study.  Subjects with PA had 
a higher prevalence of coronary artery disease, nonfatal myocardial infarction, 
congestive heart failure and atrial fibrillation.  These data underscore the adverse 
effects of excess aldosterone and indicate that the higher rate of cardiovascular 
complications in PA are at least in part independent of blood pressure. 
There are evidence that within the excess cardiovascular damage, left ventricular 
hypertrophy, is reversible upon instauration of specific treatment: in a recent 
clinical trial(31) 180 patients with PA were prospectively followed using serial 
echocardiogram and compared to 143 patients with EH.  At baseline, the subjects 
with PA had greater LV mass than matched patients with EH.  At a mean follow 
up of 36 months, the subgroup with APA who underwent adrenalectomy had 
similar BP control as those treated with mineralocorticoid antagonists and those 
with EH.  This was accompanied by a significant regression of LVH and LV mass 
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by reverse inward LV remodeling in both the surgically and medically treated 
group of patients with PA during the study. 
Aldosterone excess also has been shown to contribute to structural damage in the 
kidney and its implication in the pathogenesis of renal injury.(33, 34)  Moreover, in 
the PAPY study(24) (PA Prevalence in Hypertensives) patients with PA had higher 
urinary albumin excretion than comparably matched subjects with EH.  In a 
multicenter German Conn’s Registry study(35) was results that chronic renal 
insufficiency was more common in subjects with PA than in hypertensive controls 
(29% vs. 10%). 
Hence, early identification of PA is crucial for preventing complications, and 
reversing pre-existing cardiovascular damage by specific therapy.(14, 26) 
Removal of aldosterone excess by adrenalectomy normalizes BP despite 
withdrawal or tapering of antihypertensive therapy in up to 82% of the patients 
and prevents the development and/or induces regression of adverse 
cardiovascular changes in most patients.(36, 37)  Similar regression of target organ 
damage can be probably achieved by mineralocorticoid receptor blockade 
(spironolactone or eplerenone) at the price of life-long drug treatment.(38)  These 
considerations support an aggressive strategy aimed at making a nearly diagnosis 
and instituting specific treatment of PA.  
1.2 Prevalence of PA 
For many years after its discovery, PA was held to be a “rare bird”, even though 
Dr. Conn claimed that its prevalence was probably about 7,3% of all hypertensive 
patients.(39)  This because initially as case detection of PA was usually limited only 
to hypertensive patients with hypokalemia, though not all patients with PA have 
had hypokalemia.  The first case of patient with PA who was eukalemic was 
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reported by Conn(40) in 1965  and afterwards, Hiramatsu’s group reported that six 
of nine patients diagnosed with PA, using the Aldosterone-to-Renin Ratio (ARR, 
see below) as the initial screening method, had normokalemia.(41)  Over the last 
two decades, it has been recognized that the majority of patients with primary 
aldosteronism do not have hypokalemia.(41-43)  However, the debate on its 
prevalence went on for many decades and Gordon et al.(44) were one of the first 
groups to report that PA was more prevalent than previously realized.  They 
estimated that the incidence of PA the 'essential hypertensive' population is 
between 5 and 15%, and is probably around 10%. 
Nowadays there is consensus among experts that the PA may be far more prevalent 
than usually held.(45-47)  In one review(48) from 2003 by most estimates, 5 to 13% 
of all patients with hypertension have PA.  In 2004, a meta-analysis(49) of the rates 
reported over a decade showed estimates of prevalence from 1.4% to 32% (median, 
8.8%) thus demonstrating that the true prevalence rate was unknown.(50) 
In 2005, the results of the first large prospective study, the PAPY Study(53), PA was 
found in over of 11% of patients and 4.8% of all patients who were screened had a 
surgically curable subtype.  This results evidence that PA is the most common 
curable form of hypertension in hypertensive patients referred to specialist centers 
(with or without drug-resistant hypertension).  
Also, in general practice it has been reported that an elevated ARR involved 32.4% 
of the hypertensive individuals (with increased prevalence in females and in 
people over 55 year old), randomly selected from the general population, even 
though only a minority of them might have PA.(54) 
Moreover, patients with resistant hypertension have an even higher incidence of 
PA with the prevalence of PA between 11 and 23%.  Mosso et al.(55) evaluated over 
600 patients and they reported that 13% of patients with stage 3 hypertension had 
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PA.  In Birmingham, 88 consecutive patients with resistant hypertension 
underwent testing and 20% were found to have PA.(56)  Gallay et al.(57) screened 
90 consecutive patients with resistant hypertension and found a 17% prevalence of 
PA  and similar results were found by Eide et al.(58)  In a prospective study of 100 
consecutive patients with type 2 diabetes and resistant hypertension, Umpierrez 
et al.(59) found that 14% had primary aldosteronism and in a large retrospective 
study of 1616 patients with resistant hypertension, Douma et al.(60) found that 
11% were confirmed as having PA. 
1.3 Classification of PA 
Although there are several classifications of PA, from the practical standpoint, the 
most useful classification of form of PA is that presented in Table 1, which 
distinguishes surgically-curable from surgically-non curable causes.(61) 
 Surgically curable Not surgically curable 
1 
Aldosterone-producing adenoma (APA) 
- unilateral 
- bilateral 
Bilateral adrenal hyperplasia (BAH) 
2 Primary unilateral adrenal hyperplasia (PAH)  Unilateral APA with BAH 
3 
Multinodular unilateral adrenocortical 
hyperplasia (MUAN) 
Familial type I hyperaldosteronism  (FHI) or 
Glucocorticoid-remediable aldosteronism (GRA) 
4  Ovary aldosterone-secreting tumor  Familial type II hyperaldosteronism (FHII) 
5 
APA or bilateral adrenal hyperplasia (BAH) 
with concomitant pheochromocytoma 
Familial type III hyperaldosteronism (FH III) 
6 Aldosterone-producing carcinoma (APC) 
Apparent mineralocorticoid excess (AME) 
- Chronic licorice intake 
- Carbenoxolone (antacid) use 
   
Table 1. Classification of PA. 
 
It is crucial to identify surgically-curable from surgically-uncurable form for 
selecting the most appropriate treatment.  PA deriving from bilateral aldosterone 
excess (predominantly from bilateral adrenal hyperplasia, IHA) are optimally 
treated with life-long mineralocorticoid receptor blockade (with spironolactone, 
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canrenone, potassium canrenoate, or eplerenone), and PA form due to unilateral 
overproduction of the hormone (predominantly aldosterone-producing adenoma, 
APA) may be treated with unilateral adrenalectomy.(62) 
 
1.4 Screening strategy for PA 
The Endocrine Society guidelines(63) suggest that screening for PA should be 
undertaken in all patients with a higher pre-test probability of PA (Table 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Patients with high pre-test probability of PA. 
 
Some author(62) added other three categories of patients that were not included in 
this classification because accumulating evidence indicates that these patients 
carry a higher risk of PA: the patients with evidence of organ damage that is 
disproportionate for the severity of  hypertension, those with obstructive sleep 
apnea and the obese patients with hypertension. 
The evidence that there is a relationship between obesity, the metabolic syndrome 
and PA were confirmed in an prospective evaluation of consecutive hypertensive 
patients referred to specialized hypertension centers, where was found that body 
mass index (BMI) correlated with plasma aldosterone concentration (PAC) 
 Higher pre-test probability of PA 
1 
Unexplained hypokalemia (spontaneous or diuretic-induced) 
2 
Resistant hypertension and hypertension grade 2 or 3  
3 Early onset (juvenile) hypertension and/or stroke (<50years) 
4 Incidentally discovered apparently non functioning adrenal mass 
(“Incidentaloma”) 
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independently of age, sex, and sodium intake in EH, but not in PA patients.  This 
association of BMI is particularly evident in overweight-obese EH patients, and 
suggests a pathophysiological link between visceral adiposity 
and aldosterone secretion.(64)  Moreover, in one prospective study of 466 patients 
with hypertension, the prevalence of the metabolic syndrome was 41.1% in subjects 
with PA and 29.6% in those with essential hypertension.(65)  In a recent study,(93) 
PA patients were compared to patients with essential hypertension, and there are 
evidence that aldosterone excess has a direct negative effect on β-cell function in 
patients with PA, and after adrenalectomy, glucose-induced first-phase insulin 
secretion improves significantly.  Obstructive sleep apnea was present in 85% of 
subjects with resistant hypertension in one study(66) and additionally, there was a 
significant correlation between PAC and the severity of sleep apnea.  In another 
study that involve 109 patients with resistant hypertension, 77% of the subjects had 
obstructive sleep apnea and 28% had hyperaldosteronism.(67) 
1.5 Diagnostic strategy for PA 
The first step for diagnosis of PA is demonstration of excess aldosterone secretion 
autonomous of RAAS.  To this end the screening test is based on the aldosterone–
renin ratio (ARR), which is calculated as the ratio between plasma renin activity 
and aldosterone concentration.   
Dunn and Espiner(68) were the first to report using ARR for screening of PA.  The 
validity of using an aldosterone to plasma renin ratio as well as the aldosterone 
level in screening patients for PA was confirmed by Weinberger’s group, they 
evaluated the ARR in a study of patients with PA and compared to subjects with 
EH and to normotensive controls and confirmed that the ratio was valid.(69)  In an 
retrospective analysis of the data from five PA centers that used a ARR as a 
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screening test reported that this test lead to a 5- to 15-fold increase in the number 
of patients diagnosed with PA.(43)  
However, the use of ARR requires careful consideration of several issues.  First of 
all, the ARR depends not just on the PAC, but also on the plasma renin activity 
(PRA), which means that all the patients with suppressed PRA will have an 
increased ARR even if the PAC is not elevated.  Hence, the ratio must be interpreted 
in light of the PAC itself, which should be higher than 15ng/dL, and of the lowest 
detectable level of the renin assay that is being used.  Therefore, it is common to 
arbitrarily fix minimum values, 0.2ng/mL/h for the PRA and 0.6mIU/dL 
(0.36ng/mL) for the direct renin activity (DRA) where used.(50, 51) 
These precautions are crucial in the elderly and black populations, which usually 
exhibit low PRA values.(70)  Aldosterone levels also rise during the luteal phase of 
the menstrual cycle(71) and increase up to 10-times normal during the third 
trimester of pregnancy.(72)  Moreover, aldosterone concentrations are also elevated 
in secondary aldosteronism due to increased renin and angiotensin levels (renal 
artery stenosis and in renin-secreting tumors).  Secondary aldosteronism also 
occurs in chronic edematous states (such as congestive heart failure), cirrhosis and 
the nephrotic syndrome.  
Other important consideration is that the PAC and renin values, and thereby the 
ARR, are markedly affected by many antihypertensive drugs (Table 3) and 
therefore before measuring the ARR, drug treatment must be appropriately 
modified before performing this test.  There are antihypertensive drugs that does 
not significantly affect the renin-angiotensin aldosterone system are doxazosin and 
the long-acting calcium channel blocker.(51)  Hence, these agents can be used 
(alone or in combination) to control BP when ever it is harmful to interrupt 
antihypertensive treatment during screening.(51)  Beta blockers must be 
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withdrawn at least 4 weeks before the test to avoid greatly increasing the false 
positive rate.  Diuretics should be withdrawn at least 3 weeks before, and MR 
antagonists should be withdrawn 6 weeks before the test, to lower the rate of false 
negative diagnoses.  Angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs) increase false negative results and they 
should be withdrawn at least 3 weeks before performing the ARR assay.  
Drug PAC PRA ARR Results 
β -Blockers ↓ ↓↓ ↑ FP 
α2-Blockers ↓ ↓↓ ↑ FP 
Diuretics →↑ ↑↑ ↓ FN 
MR antagonists ↑ ↑↑ ↓ FN 
ACEi ↓ ↑↑ ↓ FN 
ARBs ↓ ↑↑ ↓ FN 
 
Table 3. Effects of antihypertensive drugs on PAC, PRA and ARR.  PAC=plasma aldosterone 
concentration, PRA=plasma renin activity, ARR= Aldosterone-Renin-Ratio, ACEi= angiotensin I converting 
enzyme inhibitors, ARBs= angiotensin II type 1 receptors blockers. FP: false positive, FN: false negative. 
 
However, before altering the antihypertensive regimen, it is important to consider 
the risks for an individual patient with hypertension. Following a change in 
antihypertensive medications, there is a risk of development of a hypertensive 
crisis, heart failure or atrial fibrillation.  In a study by Fischer et al.(73) only 60% of 
their cohort could be switched off medications or have the medications adjusted 
during screening and confirmation of PA. 
As for all quantitative tests, as the cut off value for the ARR becomes more 
stringent, the number of false positives decreases.  The choice of the optimal cut 
off value, which has a profound impact on the diagnostic performance of the ARR, 
was based on a careful valuation of the performance of the test in only a few 
studies.(51, 74)  Using the diagnosis of APA as reference, the PAPY study(51) 
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investigators determined experimentally that the optimal cutoff was 26, which 
corresponded to a sensitivity of 80.5% and a specificity of 84.5%.  Moreover, they 
also showed that if the patients adequately prepared and if the minimum value of 
renin has been fixed, a markedly elevated ARR usually indicates the presence of 
PA.  In fact, when repeated twice in the same patient under carefully standardized 
conditions, the ARR was found to be reproducible.(75) 
For identification of false positive cases and exclusion of this cases before the 
patient selection for AVS, after the identification of patients with possible 
aldosterone overproduction with definition of ARR, four confirmatory testing 
procedures are in common use: oral sodium loading, saline infusion, 
fludrocortisone with salt loading, and the captopril challenge.(45, 47)  All these 
tests are aimed at demonstrating a non suppressible aldosterone excess after 
blunting the RAAS (renin angiotensin aldosterone system) and they rely on the 
assumption that PA is autonomous from the RAAS.(76-78)  Of note, all this test 
serve to identify false positive results and therefore to exclude these patients from 
AVS.  As they are intended to show a fall of PAC, given that hypokalemia blunts 
aldosterone secretion and therefore may prevent detection of the blunting effect of 
the test, these maneuvers must be performed only after correction of the 
hypokalemia with oral or intravenous potassium supplementation.  Of note, all 
those test serves to identify false positive results and therefore to exclude these 
patients from adrenal vein sampling (AVS).  Moreover, at the prevalence rate of PA 
typically scan at referral centers they have a negative predictive value much higher 
than their positive predictive value.  Therefore, they should be defined as exclusion 
tests instead of confirmatory tests. 
 
 
22 
 
1.6 Differentiation of Subtypes   
A. Anatomic Imaging 
All patients who have confirmed PA should undergo to anatomic imaging of the 
adrenal glands.  High-resolution Computed Tomography (CT) of the upper 
abdomen is the best available technique for identifying adrenal nodules that can 
be an APA, primary unilateral adrenal hyperplasia (PAH) or bilateral adrenal 
hyperplasia (BAH).  Magnetic resonance imaging (MRI) is another option, 
particularly if the patient cannot receive contrast.  MRI can be slightly more 
sensitive, but it is less specific and more susceptible to motion artifacts.  Although 
CT scans and MRI are useful to identify the large, rare, and usually fatal 
aldosterone-producing carcinoma(79, 80) they miss up to 42% of the APA that are 
smaller than 6 mm.  Likewise, PAH and multinodular unilateral adrenocortical 
hyperplasia (MUAN)(81) are undetectable with these imaging technologies.  
Moreover, a non functioning adrenal mass can coexist with a small, CT-
undetectable APA by chance in a hypertensive patient with a biochemical picture 
of PA.  Furthermore, in a patient with PA an adrenal nodule can be an APA but 
also a macronodule of hyperplasia in a patient with idiopathic hyperaldosteronism 
(IHA)(82) micronodules in a patient with MUAN(81) or an apparently non 
functioning, incidentally discovered adenoma (“incidentaloma”), which is 
common at autopsy even in normotensive individuals.(83) 
For all these reasons, adrenal imaging is not appropriate to achieve discrimination 
between APA and IHA, as shown by a study of PA patients who underwent both 
CT and AVS, which was used as the “gold standard” for the diagnosis.  In a study 
the CT scans mistakenly suggested an APA in 24.2% of the patients, correctly 
identified a unilateral or bilateral aldosterone excess in only 53%; falsely suggested 
BAH in 21.2 % of the patients with a unilateral source of aldosterone excess, and 
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showed the presence of an APA in the wrong adrenal in 6% of the patients.(84)  
Similar data on the incorrect diagnosis of CT for diagnosing the surgically curable 
subtypes of PA have been reported in one meta-analysis where was found that 
when AVS is used as the criterion standard test for diagnosing laterality of 
aldosterone secretion in patients with PA, CT/MRI misdiagnosed the cause of 
primary aldosteronism in 37.8% of patients.(85)  Thus, overall CT results are 
confounding in about half of the patients, can lead to useless or inappropriate 
adrenalectomy in one quarter of patients, and can exclude from adrenalectomy 
roughly one quarter of patients who are potentially curable with this procedure.  
Because of these limitations of imaging, there is a consensus that the “gold 
standard” test for showing the lateralization of aldosterone secretion is the 
measurement of PAC and plasma cortisol concentration (PCC) in adrenal venous 
blood.(86, 87)  
B. Adrenal Vein Sampling (AVS)  
The use of AVS test for diagnosing laterality of aldosterone secretion and therefore 
for differentiate unilateral from bilateral form of PA, started by Melby et al.(88) in 
1967.  AVS consist in sampling of venous blood draining from the adrenal veins 
(right and left) and the inferior cava vein for the measurement of aldosterone and 
cortisol levels.  The adrenal veins are catheterized through the percutaneous 
femoral vein approach in local anesthesia, Figure 1.  
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        Figure 1. Position of the catheters for blood sample during the AVS. 
 
Since both the performance and the interpretation of AVS require considerable 
experience, this test should be performed only at major referral centers.  Potential 
complications include adrenal vein dissection, adrenal hemorrhage or infarction 
and extravasations of contrast. 
1) Selection of Patients for Adrenal Venous Sampling  
Considering that AVS is an invasive and expensive test the appropriate patient 
selection is essential.  Since AVS is aimed at subtyping of PA and not at confirming 
this diagnosis, an unequivocal biochemical diagnosis of PA should be made before 
considering AVS.  Since AVS helps to distinguish between unilateral and bilateral 
aldosterone excess, both the U.S.Endocrine Society(63) and the Japan Endocrine 
Society guidelines(89) recommend that AVS be performed in all patients who are 
reasonable candidates for general anesthesia and surgery and who wish to 
undergo adrenalectomy if indicated.  AVS is not indicated where the patient 
prefers life-long medical treatment with a MR antagonist or surgery is already 
mandated by the size of the adenoma and/or other radiological features suspicious 
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of adrenocortical carcinoma.  Considering that nonfunctioning adrenocortical 
adenoma (“incidentaloma”) is infrequent in young people, a subgroup of patients 
in which AVS might not be needed includes young patients (<40years old) with 
marked PA of recent onset, as evidenced by spontaneous hypokalemia, and a clear-
cut unilateral cortical adenoma on computed adrenal imaging.(90)  However, even 
for young patients, bilateral aldosterone secretion, which occurs in those with IHA 
or familial hyperaldosteronism type I (FH-I), cannot be excluded without AVS.  
Therefore, in the patients with proven FH-I AVS is not indicated.  Moreover, 
unilateral aldosterone excess from a small CT-undetectable APA in the adrenal 
gland contralateral to a CT-detectable adrenal mass cannot be reliably identified 
without AVS. 
There is  evidence that some preoperative characteristics of the patients and their 
history of hypertension are associated with cure of hypertension following 
unilateral adrenalectomy.  The surgical cure of hypertension has been associated 
with young age,(91, 92) shorter duration of hypertension (<5 to 10 years), fewer 
antihypertensive medications (e≤2), higher preoperative BP, preoperative normal 
renal function, normal BMI (≤25 kg/m2), female gender, lack of a family history of 
hypertension,(36, 94-96) and no evidence of vascular remodeling.(31)  These 
preoperative characteristics also serve to guide the clinician and the patient in 
discussing realistic expectations of surgical outcomes. 
2) Preparation of the patient 
Careful preparation of the patient for the procedure and standardization of the 
conditions for its performance are key steps to the success of AVS.  Emotional and 
pain-related stress, which activates the hypothalamic pituitary adrenal axis with 
ensuing adrenocorticotropin-induced cortisol release from both adrenal glands, 
can be a major confounder of AVS results as it might lower the PAC to PCC ratio, 
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and thus has the potential to obscure lateralization to one of the adrenals when 
AVS is perform without cosyntropin (ACTH) administration.  The stress reaction 
occurs in most patients when starting AVS, waned rapidly (e.g. over 15 minutes), 
increases the SI on both sides at the beginning of the procedure, is likely to 
influence also the LI values when using the sequential AVS sampling.(97)  
Allowing the patient to rest quietly for at least 15 minutes before the blood 
sampling in a friendly environment with psychological assistance can also be 
useful during the procedure.  If cosyntropin is not used, AVS may be best 
performed in the morning, to avoid false-negative results due to diurnal 
fluctuation in ACTH having a more variable effect on many APAs than on the 
contralateral adrenal.  Some centers conduct AVS in outpatients, in which case time 
should, if possible, allow for the patient to be kept in the supine position possibly 
for one hour prior to AVS.(86, 98) 
AVS should be performed only after correction of the hypokalemia and timely 
withdrawal of confounding drugs.  Hypokalemia, if present, should be corrected 
with oral or intravenous potassium supplements before AVS, since hypokalemia 
decreases aldosterone secretion, and may potentially mask a unilateral aldosterone 
producing adenoma.  Careful adjustment of the antihypertensive agents before 
and during AVS is important.  Peripheral α1-adrenergic receptor blockers (e.g. 
doxazosin mesylate, prazosin hydrochloride, and terazosin hydrochloride), and/or 
the long-acting dihydropyridine or non-dihydropyridine calcium channel blockers 
(verapamil) are recommended as these agents have not confounding effect on 
renin secretion, but short-acting calcium channel blockers can blunt aldosterone 
secretion and raise the PRA and, therefore, can cause false-negative results.  Beta-
blockers by decreasing the PRA and leaving the PAC relatively unaffected raise the 
ARR; therefore, they should be stopped at least 2 weeks before the measurement 
of the PAC and renin.  Conversely, diuretics and mineralocorticoid receptor 
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antagonists should be withdrawn before 2 and 6 weeks, respectively, because they 
raise the PRA.  Angiotensin-converting enzyme (ACE) inhibitors and angiotensin 
II receptor blockers (ARBs) have an even more marked effect because they not only 
raise the PRA but also blunt aldosterone secretion, thus reducing the ARR and 
increasing false-negative results.  Therefore, they should be withdrawn at least 2 
weeks before performing the ARR.  However, in stage 3, and/or drug-resistant 
hypertensive patients, multiple agents may be necessary for achieving BP control 
before AVS and successful AVS can be achieved in these patients.  Thus, in these 
patients ACEIs, ARBs, diuretics, and beta-adrenergic blockers may be used as long 
as renin is suppressed.   
3) Performance and interpretation of adrenal venous sampling 
Catheterization of the left adrenal vein is achieved in almost 100% of the cases, in 
contrast, that of the right adrenal vein is more difficult owing to its small size and 
its draining directly into the inferior vena cava at various angles or directly into a 
small accessory hepatic vein.(98-100)  Hence, prior knowledge of the right adrenal 
vein anatomy can facilitate catheterization in difficult cases.(100)  The placement 
of the catheter tip closer to or farther from the adrenal gland can lead to spurious 
results showing concentrations of several-fold difference.  This implies that often 
just a single, absolute aldosterone and cortisol concentration can be meaningless.  
Therefore, the measurement of cortisol concentrations with calculation of the ratio 
of the hormone concentration in the blood taken from the adrenal vein over that in 
the infra-adrenal inferior vena cava, selectivity index (SI) (Table 4), is used as a 
measure of the adequacy of the cannulation and as a correction for the different 
degree of selectivity.  The right adrenal vein often shares egress with an accessory 
hepatic vein, where the concentration of cortisol and aldosterone is lower than in 
peripheral venous blood, owing to hepatic metabolism of both hormones and to 
dilution of the relatively low flow from the adrenal effluent.  Hence, on this side 
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underestimation of aldosterone and cortisol levels is the rule rather than the 
exception.  Prior identification on CT of the right adrenal vein draining into 
accessory hepatic vein, selective cannulation of the right adrenal vein by using 
suitable catheters should be undertaken instead of the common trunk of accessory 
hepatic vein and right adrenal vein.(97, 100)   
Unfortunately, there is no consensus on the cutoff value that determines the 
success of the adrenal sampling.(82, 101-103)  A thorough study in which the 
accuracy of different cutoff values of the SI was assessed by receiver operating 
characteristic (ROC) curve analysis showed that if cortisol can be precisely 
measured (eg, with coefficient of variation < 6%), SI of 1.1 or greater provides 
identification of APA with an accuracy that is not significantly worse than that 
attained with higher cutoff values.(104)  With such a criterion, selective AVS results 
can be obtained in close to 100% of cases on the left side, and between 85% and 
95.6% on the right side.(84, 101, 102, 104)  The use of more higher cutoffs(82, 84, 98, 
101-103, 105) results in a marked decrease in the number of AVS tests that are 
bilaterally selective.  With a cutoff for the SI of 1.10, the percent of bilaterally 
selective studies is around 80%; with a cutoff of 2.0, it decreases to 61%; and with 
a cutoff of 3.0, it falls to only 50%.  This issue is crucial because the availability of 
bilaterally selective AVS data is essential for a proper diagnostic use of the 
results.(84, 104) 
When bilaterally selective samples are available, most centers use the calculation 
of the lateralization index (LI) (Table 4) for establish whether a lateralized 
aldosterone excess exists.  This index is calculated from the PAC and PCC in both 
adrenal veins and defined as the ratio of the higher (dominant) over the lower 
(non-dominant) PAC/PCC ratio, over the simultaneously measured cortisol values 
to correct for the degree of selectivity (dilution).  Unfortunately, there is no 
consensus on the cutoff value that mandates adrenalectomy.  The only study that 
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prospectively explored the use of a wide range of cutoffs by performing 
adrenalectomy in patients with LI down to 2 and by formally assessing the 
performance of different cutoffs, with ROC curve analysis, supports the use of a 
cutoff value of 2.(104)  
 
Table 4. Definition of SI, LI and CSI.  PAC= plasma aldosterone concentration; PCC= plasma cortisol 
concentration; PAC dominant and PAC non dominant are PAC on the side with higher and lower aldosterone 
secretions, respectively. PCC dominant and PCC non dominant are PCC on the side with higher and lower 
aldosterone secretions, respectively. IVC= inferior vena cava. 
 
When only unilaterally selective AVS results are available for diagnostic of 
lateralization of aldosterone production, contralateral suppression is used, instead 
of a lateralization index.  This contralateral suppression, contralateral suppression 
index (CSI), is calculated from the ratio of PAC over PCC of each side and PAC 
over PCC of the infrarenal inferior vena cava (Table 4).  This index is used to 
determine if the aldosterone concentration in the adrenal vein blood is, or is not, 
higher than expected based on the peripheral arterial level of the hormone. 
4) Intra-procedural PCC assay 
Some centers have exploited the use of extemporaneous, intra-procedural PCC 
measurement for definition of selectivity of samples.  This has the advantage of 
furnishing to the radiologist the immediate feedback on whether selective blood 
Definition Formula Clinical significance 
Selectivity index (SI) PCCside/PCCIVC 
Values > the cut-off confirms 
that the blood sample was 
obtained from the adrenal 
vein. 
Lateralization index (LI) 
PACdom/PCCdom: 
PACnondom/PCCnondom 
Values > the cut-off evidence 
lateralized aldosterone excess. 
Contralateral 
suppression index (CSI) 
PACnondom/PCCnon dom : 
PACIVC/PCCIVC 
Values < the cutoff 
indicate ipsilateral suppression 
and suggest contra-
lateral aldosterone 
overproduction. 
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sampling from each adrenal vein was achieved.  In the latter case further attempts 
of selective catheterization could therefore be undertaken before removing the 
catheters, thus avoiding the need for a future catheterization.(106, 107)  While this 
approach can improve the success rate, particularly during the radiologist’s 
learning curve, it is feasible only at centers where PCC can be measured rapidly, 
which implies a suitable logistic organization and a dedicated laboratory 
technician standing by.(108, 109) 
5) Use of stimulation test during AVS 
Aldosterone and cortisol are released in bursts from the adrenals, which can bias 
the results of AVS when sequential AVS (incanulation of adrenal veins one at time) 
is performed, due to difference in timing of blood sampling.  Therefore, to 
circumvent the problems it has been proposed to perform AVS after ACTH 
stimulation of aldosterone secretion, to facilitate the demonstration of 
lateralization in APA.  Stimulation with a continuous cosyntropin infusion during 
AVS was introduced in 1979 and is currently used at many centers.(84, 110, 111)  
The reasoning for use of an ACTH infusion is that the infusion may minimize any 
stress-induced perturbations in aldosterone and cortisol during the procedure.  
This stimulation enhance the PCC gradient between the adrenal vein and the 
inferior vena cava, and thus increasing the SI values and confidence of successful 
sampling, reduce stress-induced fluctuations in cortisol and aldosterone secretion 
during sequential AVS and  increase aldosterone secretion from APA.(84, 110, 111)  
But there are evidence that ACTH stimulation markedly increases the selectivity 
index and exerts a confounding effect on the lateralization index.(87, 112-114)  Use 
of bilaterally simultaneous catheterization (bilateral simultaneous cannulation of 
both adrenal veins)(112), avoids generating differences between sides owing to the 
different timing of the blood sampling under the stressful condition represented 
by AVS,  but it might slightly increase the risk of adrenal vein thrombosis, as it 
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increases the time of catheter’s obstructing the vessel lumen until the contralateral 
vein is successfully catheterized. 
1.7 Purposes for performing the AVIS Study 
Considering this background, we decided to perform Adrenal Vein International 
Study (AVIS) because despite the high prevalence of PA, and the fact that AVS is 
crucial for discriminating between its two major subtypes and therefore for 
selecting the most appropriate treatment, marked differences remain in the use of 
AVS even at major referral centers.  This under-utilization is likely due to the 
misconception, mostly based on anecdotal experiences and/or on retrospective 
observational studies,(86) that AVS is  technically challenging, invasive, risky, and 
not always necessary.  Moreover, still today there are not accepted international 
standards for the performance of AVS and neither established criteria for 
interpretation of its results.  In particular, some centers use the bilateral 
simultaneous technique, while others perform the sequential catheterization.  
Moreover, some centers perform AVS during or after using ACTH stimulation, 
albeit with different doses, and others do not use any stimulation.  In addition, 
some are utilizing the absolute values of plasma cortisol and aldosterone to 
determinate the selectivity and lateralization, whereas others are relying on 
calculation of the selectivity index followed by calculation of the lateralization 
index.  Moreover, large differences in the cutoffs for establishing selectivity and 
lateralization exist.  
The creation of one large database, comprising data from international referral 
centers on  performance e interpretation of the AVS and information of patients’ 
outcome after the treatment decision based and AVS results, using the “four 
corners” approach(51) (Table 5), will form the basis for providing evidence-based 
guidelines in a this still controversial field. 
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Table 5. Four Corner Criteria for diagnosis of APA.  Cure: SBP<140 mmHg and/or DBP<90 mmHg 
without medications; Improvement: SBP and/or DBP <140/90 mmHg, respectively, on the same or reduced 
number of medications and/or a reduced number of defined daily doses. 
  
 “FOUR CORNERS’’ CRITERIA for diagnosing APA 
1 
Biochemical evidence of PA 
2 Unequivocal evidence of lateralized aldosterone secretion at 
bilaterally selective AVS 
3 
Evidence of adrenocortical nodule on CT/MRA imaging and/or 
surgery and/or histopathology 
4 
Post-adrenalectomy follow-up data (at least 120 days after 
adrenalectomy) 
a)Cure or improvement of hypertension 
b)Correction of the biochemical picture of PA 
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2. AIMS OF THE STUDY 
Aim 1 
The first aim of the study was collect data on how AVS is being performed across 
the refferal centers worldwide to answer the following questions: 
1. How many AVS studies were performed yearly from 2005 to 2010 per center;  
2. What is the rate of PA patients in whom AVS is performed;  
3. How many adrenal vein ruptures occurred during the AVS;  
4. Use bilaterally simultaneous or sequential AVS catheterization; 
5.  Number of radiologists that perform AVS at each center;  
6. Use of cosyntropin stimulation during AVS;  
7. Calculation of the selectivity, lateralization and contralateral suppression 
index and minimum cutoff value used;  
8. Use of AVS studies not bilaterally selective for diagnosis;  
9. Cost of AVS for the National Health System/Insurance and for patients. 
Aim 2  
In the second phase of the study we collected information on individual data of PA 
patients who were submitted to AVS.  In particular we collected information on 
the following variables: 
 Demography data (sex, age, race); 
 Weight and height of patients; 
 Presence of resistant hypertension; 
 Baseline pharmacological treatment; 
 Baseline BP and heart rate values; 
 Serum K+, plasma aldosterone and plasma renin level before AVS; 
 Dynamic test during the AVS if any; 
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 Plasma aldosterone and cortisol concentration in the infraadrenal 
inferior vena cava and in the right and left adrenal vein;  
 Final diagnosis (unilateral or bilateral APA, unilateral or bilateral 
hyperplasia, APA with hyperplasia) 
 Treatment (adrenalectomy or pharmacological therapy); 
 Post-treatment BP values; 
 Post-treatment sK+, plasma aldosterone and plasma renin level; 
 Diagnosis concordance/discordance between imaging (CT or RM) and 
AVS. 
As no consensus exists on the performance and interpretation of the AVS results, 
in the second phase of the Study we have the following aims: 
1) to assess the rate of bilaterally selective AVS studies as a function of the different 
cutoff values of the selectivity index;  
2) to identify the best cutoff value for the identification of the lateralized 
aldosterone excess;  
3) to clarify if contralateral suppression allows diagnosing lateralization when only 
unilateral (usually left-sided) AVS is successful. 
4) To assess the rate of the patients with lateralized aldosterone excess secretion 
cured by adrenalectomy;  
5) to establish whether medical therapy induces improvement of high BP pressure 
in PA subtypes characterized by bilateral aldosterone excess secretion;  
6) to assess the rate of AVS concordant /discordant with results of imaging tests. 
For reasons of time and brevity in this preliminary analysis the data on 
contralateral suppression will not be included. 
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   3. METHODS 
   3.1 Study design 
Retrospective, multi-center, observational study. 
   3.2 Center selection 
Eligible centers were identified from those that had published in English on PA 
and/or AVS in the last decade following the PICO strategy ((P, population = adults 
with PA; I, intervention = AVS; C, comparator = simultaneous AVS vs sequential 
catheterization technique, use of cosyntropin testing vs non-stimulated condition, 
use of bilaterally vs unilaterally selective AVS results, use of absolute hormonal 
data vs selectivity and lateralization indices; O, outcome = the ways AVS was 
performed and interpreted, adrenal vein rupture).(115)  Suitable studies were 
identified by computer-assisted database searches (PubMed database, U.S. 
National Library of Medicine using the key-words: aldosterone; primary 
aldosteronism; endocrine hypertension; adrenal vein sampling), scanning of 
reference lists, hand-searching of relevant journals, correspondence with authors 
of relevant reports and meeting presentations, and consultation with experts in the 
field.  Moreover, during the study recruiting centers belonging to the European 
Network for the Study of Adrenal Tumors the study size was enlarged.  Four 
centers that participated in the first phase did not take part in the second phase of 
the study. 
   3.3 Recruitment 
Invitation of the corresponding Author of each article to participate in the study.  
The flow chart of the study is shown in Figure 2. 
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                                 Figure.2. Flow chart of AVIS phase 1 
   3.4 Inclusion/exclusion criteria 
After identification of the eligible centers the only inclusion/exclusion criteria were 
the leading investigator’s agreement or unwillingness to participate in the study, 
respectively. 
   3.5 Data collection  
Data were collected in a predefined form and stored securely and anonymously 
on a server protected by firewalls and passwords at the coordinating center.  Each 
participating center  filled the database online with their own data or they sent the 
data via mail to the coordinator center.  The data were collected and handled at the 
maximum level of confidentiality under the requirement of the Declaration of 
Helsinky.  Information on categorical variables were systematically re-coded to 
maximize comparability among studies.  Data obtained from each participating 
study were checked for internal consistency and any queries then referred back, in 
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confidence, to the study collaborator(s), before harmonization to a standard 
format.  The content of the data were unchanged by this process, and computer 
generated detailed summary tabulations based on the converted data were 
reviewed and confirmed by collaborators. 
   3.6 Statistical analyses  
Statistical analysis was performed by SPSS for Mac (vers 21.0), GraphPad and the 
MedCalc softwares.  For phase 1 of the study a stepwise regression analysis 
(backward, Wald) with a p-in=0.05 and p-out=0.10 was used to identify the 
predictors (number of AVS performed by each radiologist, number of AVS 
performed by each center, use of cosyntropin stimulation, use of bilateral 
simultaneous vs sequential AVS technique) of adrenal vein rupture.  For phase 2 
specifics algorithms were used in SPSS for Mac (vers 21.0) for the analysis of the 
data.  Exploratory analysis followed by X2 were performed. 
   3.7 Definitions  
Adrenal vein rupture was defined as lumbar pain occurring during or after AVS 
plus fluoroscopic evidence of adrenal gland and/or retroperitoneal haemorrhage.  
Post-procedure imaging (eg, ultrasound, CT, or MRI) was performed to document 
this complication whenever clinically required, as judged by the lead investigator 
of each participating center.   
Selectivity index (SI), which is used to assess the selectivity of the adrenal 
catheterization based on the step-up cortisol between the adrenal vein and the 
inferior vena cava plasma, was defined as the ratio of cortisol in each adrenal vein 
blood and in the infrarenal inferior vena cava. 
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Lateralization index (LI), which is used to establish whether a lateralized 
aldosterone excess exists, was defined the ratio of aldosterone to cortisol on the 
dominant side, e.g. the side with higher aldosterone secretion, over aldosterone to 
cortisol on the non dominant side, e.g. the side with lower aldosterone secretion.   
Contralateral suppression index (CSI), which is used to determine if the 
aldosterone concentration in the adrenal vein plasma is higher then expected based 
on the peripheral arterial level of the hormone, was defined as the ratio of 
aldosterone over cortisol of each side and aldosterone over cortisol of the infrarenal 
inferior vena cava. 
Blood pressure cured, blood pressure at follow up < 140/90 mmHg without 
therapy. 
Blood pressure markedly improved, normotension at follow up on the same or 
reduced number of medications and blood pressure similar to baseline but with a 
marked decreased (> 2 drugs or >daily dose drug) of medication. 
Blood pressure markedly improved, at follow up a fall of systolic and/or diastolic 
BP > 10%, but without achievement of normotension with the same or reduced 
therapy. 
Blood pressure no improved, at follow up no fall of systolic and/or diastolic BP 
and/or need for increased number and/or dose of antihypertensive medications. 
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   4. RESULTS AVIS PHASE 1 
   4.1 Recruitment of centers 
After preliminary identification of eligible centers, 20 of 24 invited centers from 
Asia, Australia, North America, and Europe agreed to participate (Table 6).  Of the 
remaining centers, two declined and two did not respond to the invitation (Figure 
2). 
Center City State 
Principal 
Investigator/Invetigators 
Università degli studi di Padova, DIMED Padova Italy 
 
GP.Rossi, M.Barisa, D.Miotto, T.M..Seccia, 
A.C.Pessina 
Hospital of The University of Pennsylvania Philadelphia PA, USA S.Trerotola, D.Cohen 
Yokohama Rosai Hospital Yokohama  Japan T.Nishikawa, M.Omura 
Foothills Medical Centre, University of Calgary Calgary Canada G.Kline 
General Faculty Hospital, Prague Prague Czech republic J.Widimsky jr. 
University of Paris, Hopital Européen Georges 
Pompidou 
Paris Francia P.F.Plouin, L.Amar 
University of Texas Southwestern Medical 
Center 
Dallas Texas, USA R.Auchus 
Tohoku University Hospital Sendai Japan F.Satoh 
Heinrich Heine Universität Düsseldorf Düsseldorf Germany L.C.Rump, O.Vonend 
National Taiwan University Hospital Taipei, Taiwan Taiwan K.D.Wu, V.Wu 
National Hospital Organization, Kyoto Medical 
Center 
Kyoto Japan M.Naruse 
Medical College of Wisconsin 
Menomonee 
Falls 
Wisconsin, USA S.B.Magill 
Centre Hospitalier de l'Université de Montreal  Montreal Quebec, Canada A.Lacroix 
Medizinische Klinik Innenstadt Munich Germany M.Reincke, C.Degenhart, E.Fischer 
Charité Campus Mitte Berlin Germany M.Quinkler 
University hospital Wuerzburg Wuerzburg Germany B.Allolio. R. Kickuth 
Endocrine Hypertension Research Centre, 
University of Queensland School of Medicine 
Brisbane 
Queensland, 
Australia 
M.Stowasser, R. Gordon, E.Pimenta 
Tokyo Women's Medical University Tokyo Japan A.Tanabe 
Radboud University Nijmegen Medical Center Nijmegen The Netherlands J.Deinum, L. Schultze Kool 
Dipartimento di Medicina Interna e Specialità 
Mediche, Medicina 2 
Reggio Emilia Italy E.Rossi 
Table 6. List of the participating centers and investigator in AVIS phase 1 
 
   4.2 Number of AVS performed 
The database of the first phase was locked 1st October 2011.  Upon locking we 
collected information on 2604 AVS studies performed in the period from 2005 and 
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2010 at 20 referral centers worldwide.  The average total number of AVS performed 
over the 6 years at each center was 130.2 (s.e.m.= 24.4).  Figure 3 show the total 
number of AVS performed by each center in 6 years period.  The number of AVS 
performed yearly at each center showed a trend toward increasing use over time.  
The average numbers of AVS performed annually for each center was generally 
lower than 40 and ranged between 16 in 2005 and 34 in 2010 (Figure 4).   
 
Figure 3. Number of AVS performed over the 6 years period at each center. 
 
 
          Figure 4. Average number of AVS performed for each center yearly. 
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   4.3 Rate of performance of AVS  
From analysis of the data results that AVS was not offered to all patients eligible 
for adrenalectomy: the percentage of patients with confirmed PA in whom AVS 
was performed was 77% (median) but ranged widely between 19% and 100% 
across the centers (Figure 5). 
 
Figure 5. Rate of AVS use in PA patients. 
 
   4.4 Performance of AVS 
Almost two-thirds (13/20) of the centers reported using sequential catheterization 
technique (cannulation of the adrenal veins one at a time), while the remaining 7 
centers used bilateral simultaneous cannulation.  There were no differences in rate 
of adrenal vein rupture between centers using either catheterization technique. 
In terms of dynamic testing, 11 of 20 centers performed AVS with ACTH 
stimulation, and the rest without any stimulation.  Use of ACTH was not more 
common among centers that used sequential catheterization. 
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   4.5 Number of radiologists performing AVS and rate of complications 
The number of radiologists performing the procedure at each center was low, 
median 2 radiologist/center, range 1 to 7 per center (Figure 6).  The number of 
radiologist at the 20 centers was in total 51, and only at two centers were more than 
three radiologists (6 and 7, respectively) performing  AVS. 
 
                Figure 6. Number of Radiologist performing AVS per center. 
 
The number of ruptures of an adrenal vein during or after AVS, was 16, 
corresponding to an overall rate of 0.61% (Figure 7).  All resolved with conservative 
treatment and there were no deaths.  The rate differed significantly among centers: 
at one center for instance it was 10-fold higher than the average rate recorded by 
all others.  In this center the procedure was performed by radiologists in training 
and in rotation.  After exclusion of this outlier center from the analysis the rate of 
adrenal vein rupture fell to 0.51%.  
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Figure.7. Rate of complications during AVS. 
Regression analysis showed that adrenal vein rupture was predicted by the 
number of AVS performed by each radiologist ( -0.683; p=0.007) and the number 
of AVS performed per center (= 0.831; p=0.002), but not by use of ACTH 
stimulation, bilateral simultaneous vs sequential AVS technique, or by the 
continent on which the performing center was located.  A regression model with 
these two predictors (F=7.72, p=0.005) accounted for 40% of adrenal vein ruptures. 
   4.6 Use of bilaterally vs unilaterally selective AVS results 
AVS is aimed at obtaining adrenal venous blood and therefore its results are 
interpreted based on the assumption that selective blood samples have been 
obtained from each side.  Notwithstanding this, 8 of 20 centers used bilaterally 
selective studies for diagnosis, while the majority (12/20) used unilaterally selective 
studies when bilateral results were unavailable.  Use of a unilateral study is based 
on the assumption that if the patient has unequivocal evidence of PA and one side 
is suppressed (by volume expansion and high BP) then the excess aldosterone 
should come from the contralateral side.  This might be important because it can 
allow diagnosis even when the right adrenal vein cannot be successfully 
catheterized; unfortunately, it is largely theoretical and yet unsupported by specific 
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studies. 
   4.7 Interpretation of AVS results 
Wide variations in the way results are used and interpreted across centers were 
evident: one center used absolute hormonal values instead of selectivity and 
lateralization indices, while another center calculated only the lateralization index 
even for non-selective studies.  
The cutoff values for selectivity and lateralization indices varied markedly among 
those centers that systematically used them.  Figure 8 shows the proportion of 
centers using the different cutoffs for selectivity and lateralization indices under 
both non-stimulated condition and with ACTH stimulation.  Under non-
stimulated condition cutoffs were lower than during stimulated sampling for 
selectivity but not for lateralization. In terms of the selectivity index, the majority 
of the centers used a cutoff of 2 under non-stimulated conditions and 3 - 5 under 
ACTH stimulation.  For the lateralization index most centers used 2 - 4 under non-
stimulated conditions and 2.6 - 4 for ACTH-stimulation.  For the selection of the SI 
and Li cutoffs 67% of the centers relied on values reported in the literature; 11% 
reported selecting their cutoffs based on a formal assessment of diagnostic 
accuracy with ROC curves alone, and a further 11% also used the Youden index.  
In 11% of the centers the selection was made empirically with no formal analysis. 
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Figure 8. Cut off values used for the SI e LI, baseline and during ACTH stimulation 
 
Use of unilaterally selective AVS results for diagnostic purposes would imply 
reliance on contralateral suppression, instead of a lateralization index.  We 
therefore next examined how many centers used the former index and whether 
there was an association between use of unilateral selective AVS and of 
contralateral suppression.  We found that those centers that systematically relied 
on non-bilaterally selective AVS also used contralateral suppression more 
frequently than expected by chance (X2=5.90, p= 0.05).  In contrast, no significant 
correlation could be found between the use of ACTH stimulation and contralateral 
suppression. 
4.8 Costs of AVS 
The costs of AVS showed a wide variability among centers and countries, both for 
the patient and for the insurance or national health care system.  The cost ranged 
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from 80 to 10532 € for health insurance systems and from 0 to 1357 € for the patient, 
Figure 9.  
 
Figure 9. Cost of AVS in euro. Panel A. Cost of AVS across the different centers. Panel B. 
difference in the cost between different continents. 
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   5. RESULTS AVIS PHASE 2 
   5.1 Baseline Characteristics of the Patients 
Due to the delay of some centers in providing the data, we performed a 
preliminary analysis with the data available upon locking the database on 
December, 31st 2013.  When we locked the database there was information on 1030 
PA patients that undergo to AVS in 15 referral centers worldwide, Table 7.   
Center City State 
Principal 
Investigator/Invetigators 
Università degli studi di Padova, DIMED Padova Italy 
GP.Rossi, M.Barisa, D.Miotto, 
T.M..Seccia, A.C.Pessina 
Foothills Medical Centre, University of 
Calgary 
Calgary Canada G.Kline 
General Faculty Hospital, Prague Prague Czech republic J.Widimsky jr. 
University of Paris, Hopital Européen 
Georges Pompidou 
Paris Francia P.F.Plouin, L.Amar 
Tohoku University Hospital Sendai Japan F.Satoh 
Heinrich Heine Universität Düsseldorf Düsseldorf Germany L.C.Rump, O.Vonend 
National Taiwan University Hospital Taipei Taiwan K.D.Wu, V.Wu 
National Hospital Organization, Kyoto 
Medical Center 
Kyoto Japan M.Naruse 
Medical College of Wisconsin Menomonee Falls Wisconsin, USA S.B.Magill 
Medizinische Klinik Innenstadt Munich Germany M.Reincke, C.Degenhart, E.Fischer 
Charité Campus Mitte Berlin Germany M.Quinkler 
Tokyo Women's Medical University Tokyo Japan A.Tanabe 
Radboud University Nijmegen Medical 
Center 
Nijmegen The Netherlands J.Deinum, L. Schultze Kool 
Dipartimento di Medicina Interna e 
Specialità Mediche, Medicina 2 
Reggio Emilia Italy E.Rossi 
University Hospital Duesseldorf, 
Dept. of Endocrinology, Diabetes and 
Rheumatology 
Düsseldorf Germany H.S. Willenberg 
 
Table 7. List of the participating centers and investigator in AVIS phase 2. 
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The baseline data of the patients are shown in Table 8.  The average age of the 
patients was 51 years, 59% were men and 41% women.  As regards race, the 
majority were Caucasian.  At baseline the mean value of blood pressure were 
155/93 mmHg for systolic and diastolic blood pressure, respectively, and 43.3% of 
patients were defined with resistant hypertension (defined as blood pressure that 
remained above treatment goals despite administration of an optimal three drug 
regimen that included a diuretic).  In addition, at baseline, the median serum 
potassium level was 3.6 mmol/L.  
Variable Patients, N=1030 
Age (yrs) 51.4 (16-79) 
Gender (male/female), % 59/41 
Race:    Caucasian 
             Asian 
             African 
             Hispanic, % 
77.7 
18.6 
2.9 
0.8 
Body Mass Index 28.4 
Systolic BP, mmHg 155 
Diastolic BP, mmHg 93 
HR, beats/min 73 
Serum K+ baseline, mmol/L  3.6 
Resistant Hypertension, % 43 
 
Table 8. Baseline data of the Patients. 
 
5.2 Blood pressure evaluation on follow up 
Overall, at follow up about 19% of patient were cured from high BP while 49% 
patients had a markedly improved control of their high BP with either 
pharmacological or surgical treatment.  About one fourth of the patients showed 
only a mild improvement of BP; in 8% there was no improvement of BP.  
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The analysis evidenced significant differences of BP outcome between gender and 
race: women had a better outcome when compared to men, p<0.005.  As regards 
race, Caucasian and African have better outcome then the Asian and Hispanic, 
p<0.005. 
We performed the analysis of BP outcome dividing the patients in 2 group by 
pharmacological or surgical treatment.  In the medically treated group BP was 
cured in only 1% of cases, markedly improved BP in 53%, and mildly improved BP 
in 34 %.  In 12% of the patients there was no improvement of BP (Table 8).  In the 
adrenalectomized patients, BP was cured in 34% of cases, markedly improved in 
45% of patients, and mild improvement in 16% of patients.  In 5% of the patient 
there was no improvement of BP (Table 9).   
 
 
BP Outcome 
% of Patients  
 
Definition 
Adrenalectomy 
Pharmacological 
Treatment 
 
Cured 
 
34 
 
1 
BP < 140/90 mmHg without 
therapy. 
 
Marked 
Improvement 
 
45 
 
53 
Normotension on the same or 
reduced number of medications 
and BP similar to baseline but 
with a marked decreased (> 2 
drugs or >DDD) of medication. 
 
Mild 
Improvement 
 
16 
 
34 
A fall of systolic and/or diastolic 
BP > 10%, but without 
achievement of normotension 
with the same or reduced 
therapy. 
 
No Improvement 
 
5 
 
12 
No fall of systolic and/or 
diastolic BP and/or need for 
increased number and/or dose of 
antihypertensive medications. 
 
Table 9. Blood Pressure Outcome at follow up, with pharmacological treatment or after the    
adrenalectomy; BP=blood pressure, DDD= daily dose drug. 
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Moreover, the median percentage of the patients that underwent adrenalectomy 
was lower (53%) than expected (range: 17% - 90%), with a high variability among 
centers (p<0.0001, X2= 82,73), Figure 10.  There was no significant difference 
between the genders, adrenalectomy was performed in 51.7% of the women and 
54.9% of the men.  In addition, we found significant differences among races: 
Caucasian were more frequently submitted to adrenalectomy when compared to 
Asian, African and Hispanic (p<0.0001, X2 30.36), Figure 11.  However, the number 
of Hispanic e African patients was small, thus exposing this finding to a potential 
bias.   
 
 
Figure 10. Percentage of patients submitted to adrenalectomy in each center. 
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       Figure 11. Different  rate of adrenalectomy performance by race. 
 
   5.3 Improvement of high BP with medical therapy in PA with bilateral 
aldosterone excess 
The analysis evidenced that in the patients with bilateral aldosterone excess there 
were no cases that showed cured o marked improved control of high BP with 
pharmacological treatment.  At follow up, the majority of the patients (about 75%) 
showed only a mildly improved control of BP, and 24% of the patients had no 
improvement. 
   5.4 Bilaterally selective AVS studies as function of SI cut-off   
The cut off values used at the different centers to assess the selectivity of the studies 
ranged between the 1.1 and 3.0 under non-stimulated conditions and between the 
1.1 and 7.82 under ACTH stimulation.  We analyzed the rate of bilaterally selective 
AVS studies as a function of different cutoff values and, as expected, found that 
the lower SI cutoff values were associated with a higher number of bilaterally 
selective studies (Figure 12), with no significant difference between the genders. 
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Figure 12. Bilaterally selective AVS studies as a function of the different cutoff values of 
the SI, baseline (A) and under ACTH stimulation (B). 
 
   5.5 Best cut off value for identification of the lateralized aldosterone excess 
and rate of the patients with lateralized aldosterone excess cured by 
adrenalectomy 
The cutoff values used across the centers to assess the lateralized aldosterone 
excess ranged between the 2.0 and 5.0 under non-stimulated conditions and 
between the 2.0 and 4.0 under ACTH stimulation.  The analysis of the of rate of 
lateralized AVS studies as a function of the different cutoffs evidenced that higher 
LI  values was related to  lower rate of patients diagnosed with lateralized 
aldosterone excess (Figure 13). 
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Figure 13. Lateralized aldosterone excess as a function of the different cutoff values of the LI, 
baseline (A) and under ACTH stimulation (B). 
 
 
To evaluate the best cutoff value for identifying a lateralized aldosterone excess we 
examined in the bilaterally selective studies, as determined using different SI 
cutoffs (1.10. 1.36, 1.50, 2.0 and 3.0), the performance of the different LI used in 
different centers (2.0, 2.6, 3.0, 4.0, 4.7 and 5.0) for the identification of the patients 
who were cured o markedly improved at follow up after the adrenalectomy.  This 
analysis evidenced that, at each SI, the higher the LI cutoff value the higher was 
the rate of patients with cured or markedly improved  BP control.  However, as 
already mentioned, the higher the SI cutoffs the lower the number of bilaterally 
selective patients and therefore the lower the number of patients who could be 
selected for adrenalectomy. 
   5.6 Rate of AVS concordant /discordant with results of imaging tests 
We performed a Chi square analysis to establish the rate of 
concordance/discordance between AVS results and CT imaging results for the 
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diagnosis of lateralized aldosterone excess.  Using the cut off value of LI= 4.0 under 
unstimulated (baseline) conditions we found the rate of concordance was low, both 
on the right side (26%) and on the left side (45%).  After ACTH stimulation the 
concordance rate was 28% on the right and 49% on the left side.   
Moreover, we performed the analysis in patients who had bilaterally selective AVS, 
evidence of lateralized aldosterone excess, who were submitted to adrenalectomy 
and were cured or presented markedly improved BP at follow up.  This analysis 
evidence that in this subgroup of patients the rate of concordance between AVS 
results and CT imaging results was low, 65% on the left side and 57% on the right 
side.  However, the limitation of this analysis entails the low number of patients 
who could be included, e.g. 202 patients for the left side, and 116 patients for the 
right side.  
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6. DISCUSSION  
By performing Phase 1 of the AVIS study we were able to gather novel information 
on the way in which AVS is performed and interpreted at 20 referral centers 
worldwide.  There are several important findings in this study. The first concerns 
the rate with which the AVS is performed in PA patients at these referral centers 
worldwide.  To some surprise, despite the Endocrine Society guidelines(63) 
recommendation that AVS should be used in all patients with confirmed PA who 
are candidate for adrenalectomy and seek surgical cure, the Phase 1 of AVIS 
showed that AVS was systematically performed in only about 80% (median 77%; 
range: 19% to 100%) of patients with confirmed PA.  Thus, it is altogether evident 
that even at major referral centers the therapeutic decisions for PA are not based 
on AVS in about one every five, e.g. a substantial proportion of the PA patients.  
Such a low AVS rate might depend on several factors including reliance on imaging 
tests, costs, and lack of expertise in AVS or surgery, or preference to use medical 
management alone.  However, it is of concern that adoption of an imaging-based 
strategy in the rest of the patients may well be suboptimal, because it bears the risk 
of denying curative adrenalectomy in about 20% of patients, performing 
unnecessary adrenalectomy in 15% - 25%, and removing the wrong adrenal in 
almost 4%, as shown in the Mayo clinic series and in a recent systematic review.(84, 
85)  The low accuracy of CT alone for diagnosing APA was recently 
confirmed,(116) even though two retrospective studies claimed that an imaging-
based strategy did not perform significantly worse than an AVS-based strategy for 
selecting the patients for surgery, at least when assessed in terms of blood pressure 
lowering and correction of hypokalemia,(117, 118).  The Mayo Clinic approach is 
currently to avoid AVS in patients who have unequivocal PA, are younger than 40 
years and have a single node in one adrenal and an entirely normal contralateral 
gland at CT.(127)  This is based on the premise that non functioning adrenocortical 
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adenoma (incidentaloma) are rare before 50  and therefore a single node in a young 
PA patient should be the culprit of PA.  More recently, recognizing the fallacies of 
this approach a strategy based on score calculated from CT findings,  eGFR, and 
hypokaliemia was proposed to avoid the need of AVS (90).  Of note, the results of 
this study were not confirmed in two following studies, one  already published 
(119) and another one in publication (Scott Trerotola et al, personal 
communication).  Hence, it can be concluded that there are no valid substitutions 
to AVS at present and therefore the test should be more widely used given that it 
is safe.  
In fact, a second major finding of this study is the minimal (0.61%) overall rate of 
adrenal vein rupture.  Moreover, this rate was probably an overestimate in that one 
center reported a much higher rate than all the other centers.  This anomaly 
reflected assignment at that center of radiologists in training and in rotation, to 
perform the procedure, which might account for this unusual rate.  The finding 
that the number of AVS performed by each radiologist is a strong predictor of 
adrenal vein rupture supports this.  Thus, these results disprove the concept that 
AVS per se is a risky procedure, and do not contradict the Endocrine Society 
Practice Guidelines recommending that AVS should be offered to all PA patients 
who are candidates for adrenalectomy and seek a surgical resolution of PA.(63) 
The average numbers of AVS performed annually for each center was generally 
lower than 40 and ranged between 16 in 2005 and 34 in 2010 (Fig. 4), but it showed 
a trend toward increasing use over time.  The number of radiologists performing 
the procedure at each center was low, on average 2,6.  It is likely that the low 
number of radiologists involved at each procedure, by promoting the development 
of enhanced expertise in those individuals, contributed to the low rate of 
complications. 
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AVS technique and stimulation test 
A further important result of this survey is that each center uses their own 
guidelines and criteria, which testifies the little uniformity in the way each center 
performed AVS and interpreted its data.  Initially AVS involved sequential 
catheterization - catheterization of one adrenal vein followed by the other adrenal 
vein.  However, since aldosterone and cortisol are release in bursts from the 
adrenals, which can bias the results of AVS due to difference in timing of blood 
sampling if sequential catheterization is used Weinberger et al.(110) in 1979 
proposed the strategy of maximally stimulating hormone secretion with ACTH 
infusion.  Simultaneous bilateral catheterization was then introduced in 1980 to 
minimize differences between the sides due to timing (120) and then improved 
with use of differently shaped catheters on each side.(112)   This technique might 
therefore be performed without cosyntropin stimulation.  In spite of this, only 7/20 
centers reported adopting simultaneous bilateral AVS, with the majority still 
relying on sequential catheterization with or without cosyntropin stimulation.  
Reasons for this may include the added technical difficulties inherent with 
attempting to successfully catheterize both adrenal veins at the same time.   
The Phase I AVIS also showed that centers were almost equally divided between 
those using and not using cosyntropin stimulation.  As stimulation might appear 
to be necessary when the sequential catheterization is used, we hypothesized that 
the use of cosyntropin stimulation might be associated with sequential 
catheterization but this was not the case: performing the sequential sampling was 
not more common at the centers that used the cosyntropin stimulation. 
Clinical use and interpretation of AVS 
A basic assumption underlying the appropriate diagnostic utility of AVS is 
obtaining adrenal vein blood with minimal dilution from extra-adrenal sources.  
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This means that the proper placement of the catheter into the adrenal vein should 
be verified.  This is generally accomplished by measuring the cortisol step-up 
between blood from the infrarenal inferior vena cava and blood from each adrenal 
vein to thereby calculate the selectivity index.(87)  Moreover, as the level of both 
cortisol and aldosterone in adrenal vein blood is highly dependent upon the 
proximity of the catheter tip to the adrenal cortex, it is necessary to correct 
aldosterone levels against those of cortisol when assessing lateralization.  These 
reasons support using the selectivity index and the lateralization index for optimal 
benefit for patients undergoing AVS.  Several centers did not use one or both 
indices; this was unexpected, and of concern that it may lead to sub optimally 
informed clinical decisions. Of interest, use of plasma metanephrines, which are 
more stable of the parental catecholamines and showed a much larger 
concentration step-down between the adrenal vein and the inferior vena cava and 
therefore could be better than cortisol for assessing  selectivity.(126)  Prospective 
studies are necessary to confirm the usefulness and practical feasibility of this 
approach. 
Finally, given that unilateral aldosterone excess would be expected to turn off 
aldosterone synthesis in (and secretion from) the contralateral adrenal gland, 
contralateral suppression has also been clinically used to lateralize PA.(121)  
However, the adrenal gland of subject receiving DOC and salt, e.g. placed in 
conditions that mimic PA and the adrenal cortex surrounding the APA,(122) can 
continue to produce aldosterone.(123)  Even though it was reported that plasma 
aldosterone concentrations are 129±60 and 498±84 ng/dl at 0 min and 30 min after 
ACTH stimulation, respectively, in ten essential hypertensive patients,(81) data on 
aldosterone plasma levels in adrenal veins or, more importantly, 
aldosterone/cortisol ratios and concurrent peripheral ratios of healthy volunteers 
subjected to similar conditions are lacking, presumably for ethical reasons.  Thus, 
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normal values of aldosterone production, and thereby the normal cut-off values, 
remain uncertain.   Accordingly, the use of the contralateral suppression index 
remains empirically based.  In spite of all these considerations contralateral 
suppression is being used in a two-thirds of the centers; in one center 
demonstration of contralateral suppression was a sine qua non indication for 
adrenalectomy. 
This study also showed that slightly less that on third of centers systematically 
used nonselective AVS for diagnostic purposes.  Even more worrying an additional 
6/20 occasionally used unilaterally selective studies, necessitating a finding of 
contralateral suppression.  Those centers that systematically relied on non-
bilaterally selective AVS also used contralateral suppression more frequently than 
expected by chance. 
Cutoff values for AVS 
The Phase I of the AVIS study documents a wide variability in the cut-off values 
used for selectivity, lateralization, and contralateral suppression, both under basal 
conditions and cosyntropin stimulation.  This variability is due in large part to 
choices of the cut-off values that were experience-guided rather than based on 
formal assessment of diagnostic performance.   
Overall the majority of the centers selected their cutoffs values for both the SI and 
the LI from the literature and only a minority based their selection on a formal 
assessment of diagnostic accuracy using ROC curve analysis alone (11%) or 
combined with the Youden Index (11%).  The only studies that have prospectively 
explored the performance of these indices under non-stimulated conditions to date 
support the choice of low values for both the selectivity and the lateralization 
index, but a recent study on patients who required a repeated AVS because of 
failure on the first attempt would suggest use of more stringent cutoffs for the 
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selectivity index.(124)  The choice of higher cut-off values for lateralization 
adopted in many centers presumably identifies patients with an increased chance 
of cure but might exclude from adrenalectomy some patients who are curable. 
Costs of AVS 
Surprisingly when specifically enquired the lead investigator at many centers was 
unaware of cost of the procedure: only 12/20 were able to provide accurate 
information on costs for insurance and/or the patient.  Cost varied widely between 
centers and countries largely reflecting the wide variability in organization of 
health care system and the minimum level of care provided in different countries. 
Rate of bilaterally selective AVS studies as a function of the different cutoff 
values of the selectivity index 
There is no consensus on the cutoff value that determines the success of the adrenal 
sampling, neither across the referral centers.  The cut off value of selectivity index 
across the participating centers ranged between the 1.1 and 3.0 under non-
stimulated conditions and between the 1.1 and 7.82 under ACTH stimulation.  We 
analyzed the rate of bilaterally selective AVS studies as a function of different 
cutoff values. 
As expected, we found that the  lower was the cutoff value of SI , the  higher was 
the number of bilaterally selective studies.  This evidenced that use of increasingly 
restrictive cutoffs, markedly decreased the number of AVS studies that are 
bilaterally selective. 
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Best cutoff value for the identification of the lateralized aldosterone excess  
There is no consensus on the cutoff value of lateralization index, which assesses 
the lateralized aldosterone excess.  Across the centers participating in this study 
this cut off ranged between the 2.0 and 5.0 under non-stimulated conditions and 
between the 2.0 and 4.0 under ACTH stimulation.  The analysis of the rate of 
lateralized AVS studies as a function of the different cutoffs evidenced that higher 
LI values were related to lower rates of patients diagnosed with lateralized 
aldosterone excess.  This analysis confirmed that at each SI, the higher was LI cutoff 
value the higher was the rate of patients with cured or markedly improved  BP 
control.   
However, the higher the value of SI cutoffs the lower was the number of bilaterally 
selective patients, and therefore the lower the number of patients who could be 
selected for adrenalectomy.  Adoption of a high cutoff for defining a lateralized 
aldosterone excess resulted in exclusion of a fairly large number of patients, who 
could be cured, from adrenalectomy. 
Improvement of hypertension with medical therapy or adrenalectomy 
We analyzed AVS data of 1.030 patients to establish the improvement of high BP  
at follow up, obtained with medical therapy in patients with bilateral aldosterone 
excess or with adrenalectomy in patients with lateralized aldosterone production.  
We distinguished four possible BP outcome: cured, markedly improved, mildly 
improved and no improvement. We found that in the patients with bilateral 
aldosterone excess treated with pharmacological therapy, at follow up, three-
quarters of the patients showed only a mildly improved control of BP, and 24% of 
the patients had no improvement.  Moreover, medical treatment, did not lead to 
cured or markedly improved outcome of BP.   
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At variance, in the patient submitted to adrenalectomy the BP was cured in 34% of 
cases, markedly improved in 45% of patients, and mild improved in 16% of 
patients.  In only 5% of the patients there were no improvement of BP.  This finding 
confirm the already known fact that removing of aldosterone excess by 
adrenalectomy normalizes BP despite withdrawal or tapering of antihypertensive 
therapy in up to 82% of the patients.(36, 37)   
Moreover, the analysis shown that only about half of the patients submitted to AVS 
underwent adrenalectomy.  There are no significant differences of gender, but 
significant differences by race: Caucasians were most frequently treated with 
surgery then Asians (X2=30.36, p<0.0001).  In some Asian centers of this study  the 
SI was not used and the cut off values used to determine lateralized aldosterone 
excess were higher then in other centers, a finding that can explain this differences.  
All these considerations support the recommendation of Endocrine Society 
guidelines to perform the screening for PA and if indicated to be submitted to AVS, 
gold standard exam for distinction between surgically-curable and surgically-non 
curable causes.  The evidence that adrenalectomy cure or markedly improve BP in 
about 80% of the cases, evidence the possibility to suspend or at least to reduce the 
medical treatment.  Considering that PA is the most common cause of endocrine 
hypertension, and since PA patients are at increased risk of target organs damage 
and cardio-renal complications, their early identification is crucial for preventing 
these complications and for reversing preexisting cardiovascular damage by 
specific therapy.  This will be also correlated to a lower cost for the national health 
system. 
 
 
63 
 
Rate of AVS concordant /discordant with results of imaging tests. 
The analyses performed in phase 2 of the study confirm the well known low 
accuracy of imaging test for diagnosing lateralized aldosterone excess.  This study 
evidenced that the rate of concordance between imaging data e AVS data was low: 
using the cut off value of LI = 4, we found the concordance was less than 50% on 
the left side and less than 30% on the right side, both at baseline and after 
stimulation with ACTH.   
The low accuracy of imaging data alone was confirmed by analyses of subgroups 
of patients with confirmed diagnosis of APA by the four corner criteria approach.  
In this APA patients the imaging data not identified about 35% of APA on left side 
and about 43% on the right side.  However, the limitation of this analysis entails 
the low number of patients who could be included. 
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6. CONCLUSIONS 
Despite the high prevalence of primary aldosteronism, and the fact that AVS is 
crucial for discriminating between its two major subtypes and therefore for 
selecting the most appropriate treatment, marked differences remain in the use of 
AVS even at major referral centers.  The results of Phase 1 of the AVIS study with 
the strength of a large size entailing data from 2604 AVS procedures documented 
the existence of a low complication rate and marked dissimilarities in the 
percentage of use, protocols, and interpretation and cost of AVS among the major 
referral centers around the world.   
Importantly, overall the rate of major complications was minimal which 
demonstrates that although being generally regarded as a risky procedure, AVS is 
in truth safe in experienced hands.  This observation therefore supports the 
Endocrine Society recommendation that AVS should be used in all patients with 
confirmed PA who are candidate for adrenalectomy and seek surgical cure.  
Despite the introduction of bilateral simultaneous catheterization technique by 
some centers, almost two thirds of the centers continue to use the sequential 
technique and perform catheterization during cosyntropin stimulation, while only 
few centers use ACTH stimulation with bilateral simultaneous 
catheterization.(125)  Moreover, some centers rely on measurement of absolute 
hormonal values rather than indices of selectivity, lateralization, and contralateral 
suppression.   
In the second phase of the study, analysis of the individual patients data, evidence 
that a choice of more restrictive values of the selectivity and the lateralization 
index, translates to increased rates of cured and markedly improved BP at follow 
up, but this at the price of the exclusion of a greater number of patients from 
adrenalectomy. 
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